Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: A single-arm phase II clinical trial

Journal of Neuro-Oncology

Volumn 112, Issue 3, 2013, Pages 461-466

  Dinglin, Xiao Xiao ^a   Huang, Yan ^a   Liu, Hui ^a   Zeng, Yin Duo ^b   Hou, Xue ^a   Chen, Li Kun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Brain metastases; Chemotherapy; Lung adenocarcinoma; Pemetrexed; WBRT

Indexed keywords

CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CISPLATIN; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84880464060     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1079-5     Document Type: Article

References (24)

1. de Vita VT, Hellman S, Rosenberg SA (2005) Cancer, principles & practice of oncology. Lippincott Williams & Wilkins, Philadelphia
2. Davey P (2002) Brain metastases: treatment options to improve outcomes. CNS Drugs 16:325-338
3. Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin JC, Depierre A (2004) Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 45:317-323. doi: 10.1016/j.lungcan.2004.01.025
4. Figlin RA, Piantadosi S, Feld R (1988) Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med 318:1300-1305. doi: 10.1056/NEJM198805193182004
5. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR (2005) Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 23:2955-2961. doi: 10.1200/JCO.2005.08.026
6. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW, Perez-Tamayo R, Rotman M (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874-1881
7. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H (1997) The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26:14-23
8. Yawn BP, Wollan PC, Schroeder C, Gazzuola L, Mehta M (2003) Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med 86:32-37
9. DeAngelis LM (1994) Management of brain metastases. Cancer Investig 12:156-165
10. Coia LR (1992) The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23:229-238
11. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551. doi: 10.1200/JCO.2007.15. 0375
12. Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, Scagliotti G (2012) Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 13:24-30. doi: 10.1016/j.cllc.2011.05.007
13. Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U (2010) Activity of pemetrexed on brain metastases from non-small Cell lung cancer. Lung Cancer 68:264-268. doi: 10.1016/j.lungcan.2009.06.018
14. Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A, Robinet G (2011) Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 22:2466-2470. doi: 10.1093/annonc/mdr003
15. Bailon O, Chouahnia K, Augier A, Bouillet T, Billot S, Coman I, Ursu R, Belin C, Zelek L, Des Guetz G, Levy C, Carpentier AF, Morere JF (2012) Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro-oncology 14:491-495. doi: 10.1093/neuonc/nos004
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
17. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:655-661. doi: 10.1016/j.ijrobp.2009.08.025
18. Guo S, Reddy CA, Chao ST, Suh JH, Barnett GH, Vogelbaum MA, Videtic GM (2012) Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77:389-393. doi: 10.1016/j.lungcan.2012.03.028
19. Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville L, Fournel P, Quoix E, Riou R, Rebattu P, Perol M, Paillotin D, Mornex F (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12:59-67
20. Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727
21. Ma S, Xu Y, Deng Q, Yu X (2009) Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65:198-203. doi: 10.1016/j.lungcan.2008.10.028
22. Niho S, Kubota K, Nihei K, Sekine I, Sumi M, Sekiguchi R, Funai J, Enatsu S, Ohe Y, Tamura T (2012) Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. doi: 10.1016/j.cllc.2012.03.007
23. Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S, Southwood B, Wang L, McGill S, Iscoe N, Shepherd FA (2011) Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 79:1395-1401. doi: 10.1016/j.ijrobp.2010.01.014
24. Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295-1304. doi: 10.1200/JCO.2005.04.6185